Immutep (ASX: IMM) started a phase 3 clinical trial evaluating a potential combination therapy for first-line metastatic non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.
The Tacti-004 trial will assess the company's product candidate eftilagimod alfa in combination with US-based pharmaceutical company MSD's Keytruda therapy and chemotherapy, the filing said.
The trial will compare this regimen with placebo in about 750 patients globally, the filing added. Immutep expects to enroll the first patient into this study during the first quarter of fiscal 2025.
The trial will be conducted at over 150 clinical sites across more than 25 countries. Full approval to start the trial in the UK is expected soon, with additional approvals for multiple countries anticipated in the coming months.
Shares of the biotechnology company fell nearly 1% in recent Tuesday trade.
Price (AUD): $0.33, Change: $-0.003, Percent Change: -0.90%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。